查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1968612

生物製药市场分析及预测（至2035年）：依类型、产品类型、服务、技术、应用、最终用户、製程、设备、材料类型及部署模式划分

Biologics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Device, Material Type, Deployment
出版日期: | 出版商: Global Insight Services | 英文 393 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计生物製剂市场规模将从2024年的5.815亿美元成长到2034年的13.232亿美元，复合年增长率约为8.6%。生物製剂市场涵盖生物来源的治疗产品，例如蛋白质、核酸和细胞。这些生物製剂在治疗癌症和自体免疫疾病等慢性疾病方面至关重要。生物技术的进步、慢性疾病的增加以及对个人化医疗日益增长的需求是推动该市场成长的主要因素。单株抗体、基因疗法和生物相似药的创新正在拓展治疗选择并提高疗效。监管支持和策略合作进一步推动了市场成长，使生物製药成为现代疗法的基础。

生物製剂市场正经历强劲扩张，主要得益于生技和个人化医疗的进步。单株抗体领域凭藉其在治疗慢性疾病和癌症方面的显着疗效，已成为成长最快的细分市场。重组蛋白紧随其后，反映出其在治疗和疫苗领域应用范围的不断扩大。基因疗法由于基因工程和标靶治疗的创新而展现出巨大的潜力。细胞疗法领域也正蓬勃发展，干细胞研究也取得了令人瞩目的治疗成果。生物相似药的重要性日益凸显，这主要源自于市场对品牌生物製剂经济实惠替代方案的需求。这一趋势正推动医疗保健解决方案朝更易获取的方向发展。此外，市场对能够提高生物製药疗法疗效和患者依从性的先进药物递送系统的需求也在激增。生物製药公司之间的策略联盟与合作正在促进创新，加速新型生物製剂的研发，从而为市场持续成长和盈利机会奠定基础。

市场区隔
类型 单株抗体、疫苗、重组蛋白、基因治疗、细胞治疗、生物相似药、血液製品、酶
产品 治疗性蛋白质、抗体药物复合体、细胞激素、融合蛋白、生长因子、荷尔蒙、干扰素、白细胞介素
服务 合约研究、契约製造、临床试验、法规事务、品质保证、供应链管理、物流
科技 DNA定序、CRISPR、合成生物学、生物加工、奈米技术、蛋白质工程、生物列印
应用领域 肿瘤科、感染疾病、自体免疫疾病科、心血管疾病科、代谢性疾病科、神经科、眼科、皮肤科
最终用户 製药公司、生技公司、研究机构、医院、诊所、诊断检查室、学术机构
过程 上游工程、下游製程、配方、纯化、发酵、细胞培养
装置 生物反应器、离心机、层析法系统、过滤系统、混合系统
材料类型 蛋白质、抗体、核酸、细胞、病毒载体
实施表格 内部开发、外包、混合模式

市场概况：

生物製药在医药市场中持续占据主导地位，创新疗法和成熟治疗方法均占了相当大的市场份额。定价策略因生产流程的复杂程度和临床疗效而异。频繁的新治疗方法上市反映了生物技术的进步以及单株抗体、疫苗和基因疗法等一系列产品的强劲研发管线。对个人化医疗和标靶治疗的需求不断增长，正在推动市场发展。北美和欧洲是领先的市场，而亚太地区的成长则因医疗保健投资的增加和政府政策的支持而加速。生物製剂市场竞争异常激烈，主要企业都在大力投资研发以维持其竞争优势。监管至关重要，严格的核准流程会影响产品的市场准入和扩张。美国食品药物管理局管理局 (FDA) 和欧洲药品管理局 (EMA) 对安全性和有效性设定了高标准，这可能会延迟产品上市，但最终有助于增强市场信心。新兴市场蕴藏着盈利的机会，但驾驭复杂的监管环境需要战略眼光。生物製剂的未来前景光明，细胞和基因疗法的进步正在推动创新和市场发展。

主要趋势和驱动因素：

生物製剂市场正经历强劲成长，这主要得益于生物技术的进步和对个人化医疗日益增长的需求。单株抗体、细胞疗法和基因疗法的兴起是关键趋势，它们正在改变多种疾病的治疗模式。这些创新源自于对疾病机制和人类基因组的深刻理解。监管支持和加速核准流程进一步推动了市场扩张。世界各国政府都认识到生物製剂在满足未被满足的医疗需求方面的潜力，并致力于简化核准流程。此外，慢性病发病率的上升和人口老化也是推动市场发展的关键因素，促使人们寻求新的治疗方案。生物製药产业在研发方面也投入了大规模资金。各公司正致力于扩大产能和改善药物输送系统。新兴市场医疗基础设施的不断完善为市场提供了许多机会。策略联盟和伙伴关係关係日益普遍，使企业能够利用互补优势并拓展全球企业发展。在持续创新和策略性措施的推动下，生物製药市场预计将保持持续成长。

限制与挑战：

生物製药市场目前面临许多重大限制与挑战。其中一个主要挑战是生物製药的高成本，这不仅限制了病患的用药途径，也给医疗系统带来了沉重的经济负担。生物製药生产流程的复杂性进一步加剧了这个问题，需要对专业设施和熟练人员进行大量投资。此外，监管障碍也是一大挑战。生物製药严格的核准流程导致研发週期延长、成本增加，阻碍了中小企业进入市场。智慧财产权问题同样构成重大障碍，专利到期生物相似药的涌入加剧了竞争，并影响了市场占有率。地缘政治紧张局势或全球卫生危机导致的供应链中断可能造成生物製药供不应求和分销延迟。最后，低温运输物流的需求也增加了复杂性和成本，阻碍了市场扩张，尤其是在资源匮乏的地区。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 单株抗体
    • 疫苗
    • 重组蛋白
    • 基因治疗
    • 细胞疗法
    • 生物相似药
    • 血液製品
    • 酵素
  • 市场规模及预测：依产品划分
    • 治疗性蛋白质
    • 抗体药物复合体
    • 细胞激素
    • 融合蛋白
    • 生长因子
    • 荷尔蒙
    • 干扰素
    • 白细胞介素
  • 市场规模及预测：依服务划分
    • 委託研究
    • 契约製造
    • 临床试验
    • 监管服务
    • 品质保证
    • 供应链管理
    • 后勤
  • 市场规模及预测：依技术划分
    • DNA定序
    • CRISPR
    • 合成生物学
    • 生物製程
    • 奈米科技
    • 蛋白质工程
    • 生物列印
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 感染疾病
    • 自体免疫疾病
    • 心血管疾病
    • 代谢性疾病
    • 神经病学
    • 眼科
    • 皮肤科
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 研究所
    • 医院
    • 诊所
    • 诊断检查室
    • 学术机构
  • 市场规模及预测：依製程划分
    • 上游工程
    • 下游工艺
    • 配方
    • 纯化
    • 发酵
    • 细胞培养
  • 市场规模及预测：依设备划分
    • 生物反应器
    • 离心机
    • 层析法系统
    • 过滤系统
    • 混合系统
  • 市场规模及预测：依材料类型划分
    • 蛋白质
    • 抗体
    • 核酸
    • 细胞
    • 病毒载体
  • 市场规模及预测：依发展状况
    • 内部
    • 外包
    • 杂交种

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Sandoz
  • Samsung Biologics
  • Biocon
  • Catalent
  • WuXi Biologics
  • Lonza
  • Sartorius
  • Boehringer Ingelheim
  • Fujifilm Diosynth Biotechnologies
  • Abzena
  • AGC Biologics
  • Samsung Bioepis
  • Cytiva
  • Bavarian Nordic
  • MorphoSys

第九章：关于我们

简介目录
Product Code: GIS33678

Biologics Market is anticipated to expand from $581.5 million in 2024 to $1,323.2 million by 2034, growing at a CAGR of approximately 8.6%. The Biologics Market encompasses therapeutic products derived from living organisms, including proteins, nucleic acids, and cells. These biologics are pivotal in treating chronic diseases such as cancer and autoimmune disorders. The market is driven by advancements in biotechnology, increasing prevalence of chronic diseases, and rising demand for personalized medicine. Innovations in monoclonal antibodies, gene therapies, and biosimilars are expanding treatment options and enhancing efficacy. Regulatory support and strategic collaborations further propel market growth, positioning biologics as a cornerstone of modern therapeutics.

The Biologics Market is experiencing robust expansion, driven by advancements in biotechnology and personalized medicine. The monoclonal antibodies segment emerges as the top-performing sub-segment, owing to their efficacy in treating chronic diseases and cancer. Recombinant proteins follow closely, reflecting increased applications in therapeutic treatments and vaccines. Gene therapy showcases significant potential, propelled by innovations in genetic engineering and targeted treatments. The cell therapy sub-segment is gaining momentum, with stem cell research offering promising therapeutic outcomes. Biosimilars are becoming increasingly relevant, driven by the need for cost-effective alternatives to branded biologics. This trend is prompting a shift towards more accessible healthcare solutions. The market is also witnessing a surge in demand for advanced drug delivery systems, enhancing the efficacy and patient compliance of biologic treatments. Strategic partnerships and collaborations between biopharmaceutical companies are fostering innovation and accelerating the development of novel biologics, positioning the market for sustained growth and lucrative opportunities.

Market Segmentation
TypeMonoclonal Antibodies, Vaccines, Recombinant Proteins, Gene Therapy, Cell Therapy, Biosimilars, Blood Products, Enzymes
ProductTherapeutic Proteins, Antibody Drug Conjugates, Cytokines, Fusion Proteins, Growth Factors, Hormones, Interferons, Interleukins
ServicesContract Research, Contract Manufacturing, Clinical Trials, Regulatory Services, Quality Assurance, Supply Chain Management, Logistics
TechnologyDNA Sequencing, CRISPR, Synthetic Biology, Bioprocessing, Nanotechnology, Protein Engineering, Bioprinting
ApplicationOncology, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases, Metabolic Disorders, Neurology, Ophthalmology, Dermatology
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Hospitals, Clinics, Diagnostic Labs, Academic Institutions
ProcessUpstream Processing, Downstream Processing, Formulation, Purification, Fermentation, Cell Culture
DeviceBioreactors, Centrifuges, Chromatography Systems, Filtration Systems, Mixing Systems
Material TypeProteins, Antibodies, Nucleic Acids, Cells, Viral Vectors
DeploymentIn-house, Outsourced, Hybrid

Market Snapshot:

Biologics continue to dominate the pharmaceutical landscape, with significant market share held by innovative therapies and established treatments. Pricing strategies vary, driven by the complexity of production and clinical efficacy. New product launches are frequent, reflecting advancements in biotechnology and a robust pipeline of monoclonal antibodies, vaccines, and gene therapies. The market is buoyed by increasing demand for personalized medicine and targeted therapies. North America and Europe are key regions, though Asia-Pacific is witnessing accelerated growth due to rising healthcare investments and supportive government policies. Competition in the biologics market is intense, with leading companies investing heavily in R&D to maintain their competitive edge. Regulatory influences play a pivotal role, with stringent approval processes impacting market entry and expansion. The FDA and EMA set high standards, ensuring safety and efficacy, which can delay product launches but ultimately enhance market credibility. Emerging markets offer lucrative opportunities, yet navigating diverse regulatory landscapes requires strategic acumen. Biologics' future is promising, with advancements in cell and gene therapies driving innovation and market evolution.

Geographical Overview:

The biologics market is witnessing robust growth across diverse regions, each presenting unique opportunities. North America retains a dominant position, bolstered by advanced healthcare infrastructure and significant R&D investments. The presence of leading biopharmaceutical firms further drives innovation and market expansion. Europe follows, with its strong emphasis on biotechnology research and favorable regulatory frameworks enhancing market dynamics. The Asia Pacific region is experiencing rapid market growth, driven by an increasing prevalence of chronic diseases and rising healthcare expenditure. Countries like China and India are emerging as lucrative markets due to their large patient populations and government support for biotechnology. Latin America presents promising growth prospects, with Brazil and Mexico investing in healthcare advancements. The Middle East & Africa region is gradually gaining traction, with countries like the UAE and South Africa recognizing the potential of biologics in improving healthcare outcomes. These emerging markets offer significant opportunities for expansion and investment in the biologics sector.

Key Trends and Drivers:

The biologics market is experiencing robust growth, fueled by advancements in biotechnology and increased demand for personalized medicine. Key trends include the rise of monoclonal antibodies and cell and gene therapies, which are revolutionizing treatment paradigms across various diseases. These innovations are driven by a deeper understanding of disease mechanisms and the human genome. Regulatory support and expedited approval pathways are further accelerating market expansion. Governments are recognizing the potential of biologics to address unmet medical needs, thus streamlining approval processes. Additionally, the increasing prevalence of chronic diseases and aging populations are significant drivers, necessitating novel therapeutic solutions. The biopharmaceutical industry is also witnessing substantial investments in research and development. Companies are focusing on enhancing production capabilities and improving drug delivery systems. Opportunities abound in emerging markets, where healthcare infrastructure is evolving. Strategic collaborations and partnerships are becoming prevalent, enabling firms to leverage complementary strengths and expand their global footprint. The biologics market is poised for sustained growth, driven by continuous innovation and strategic initiatives.

Restraints and Challenges:

The biologics market is currently encountering several significant restraints and challenges. One of the primary challenges is the high cost of biologic drugs, which limits accessibility for patients and places a financial burden on healthcare systems. The complexity of manufacturing processes for biologics further exacerbates this issue, as it requires significant investment in specialized facilities and skilled personnel. Additionally, regulatory hurdles present another formidable challenge. The stringent approval processes for biologics can lead to prolonged timelines and increased costs, discouraging smaller companies from entering the market. Intellectual property concerns also pose a significant barrier, as patent expirations open the door to biosimilars, intensifying competition and impacting market share. Supply chain disruptions, often caused by geopolitical tensions or global health crises, can lead to shortages and delays in the distribution of biologics. Lastly, the need for cold chain logistics adds another layer of complexity and cost, hindering market expansion, particularly in low-resource settings.

Key Players:

Sandoz, Samsung Biologics, Biocon, Catalent, WuXi Biologics, Lonza, Sartorius, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, Abzena, AGC Biologics, Samsung Bioepis, Cytiva, Bavarian Nordic, MorphoSys

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Material Type
  • 2.10 Key Market Highlights by Deployment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Vaccines
    • 4.1.3 Recombinant Proteins
    • 4.1.4 Gene Therapy
    • 4.1.5 Cell Therapy
    • 4.1.6 Biosimilars
    • 4.1.7 Blood Products
    • 4.1.8 Enzymes
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Proteins
    • 4.2.2 Antibody Drug Conjugates
    • 4.2.3 Cytokines
    • 4.2.4 Fusion Proteins
    • 4.2.5 Growth Factors
    • 4.2.6 Hormones
    • 4.2.7 Interferons
    • 4.2.8 Interleukins
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Research
    • 4.3.2 Contract Manufacturing
    • 4.3.3 Clinical Trials
    • 4.3.4 Regulatory Services
    • 4.3.5 Quality Assurance
    • 4.3.6 Supply Chain Management
    • 4.3.7 Logistics
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 DNA Sequencing
    • 4.4.2 CRISPR
    • 4.4.3 Synthetic Biology
    • 4.4.4 Bioprocessing
    • 4.4.5 Nanotechnology
    • 4.4.6 Protein Engineering
    • 4.4.7 Bioprinting
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Infectious Diseases
    • 4.5.3 Autoimmune Diseases
    • 4.5.4 Cardiovascular Diseases
    • 4.5.5 Metabolic Disorders
    • 4.5.6 Neurology
    • 4.5.7 Ophthalmology
    • 4.5.8 Dermatology
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Hospitals
    • 4.6.5 Clinics
    • 4.6.6 Diagnostic Labs
    • 4.6.7 Academic Institutions
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Upstream Processing
    • 4.7.2 Downstream Processing
    • 4.7.3 Formulation
    • 4.7.4 Purification
    • 4.7.5 Fermentation
    • 4.7.6 Cell Culture
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Bioreactors
    • 4.8.2 Centrifuges
    • 4.8.3 Chromatography Systems
    • 4.8.4 Filtration Systems
    • 4.8.5 Mixing Systems
  • 4.9 Market Size & Forecast by Material Type (2020-2035)
    • 4.9.1 Proteins
    • 4.9.2 Antibodies
    • 4.9.3 Nucleic Acids
    • 4.9.4 Cells
    • 4.9.5 Viral Vectors
  • 4.10 Market Size & Forecast by Deployment (2020-2035)
    • 4.10.1 In-house
    • 4.10.2 Outsourced
    • 4.10.3 Hybrid

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Device
      • 5.2.1.9 Material Type
      • 5.2.1.10 Deployment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Device
      • 5.2.2.9 Material Type
      • 5.2.2.10 Deployment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Device
      • 5.2.3.9 Material Type
      • 5.2.3.10 Deployment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Device
      • 5.3.1.9 Material Type
      • 5.3.1.10 Deployment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Device
      • 5.3.2.9 Material Type
      • 5.3.2.10 Deployment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Device
      • 5.3.3.9 Material Type
      • 5.3.3.10 Deployment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Device
      • 5.4.1.9 Material Type
      • 5.4.1.10 Deployment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Device
      • 5.4.2.9 Material Type
      • 5.4.2.10 Deployment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Device
      • 5.4.3.9 Material Type
      • 5.4.3.10 Deployment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Device
      • 5.4.4.9 Material Type
      • 5.4.4.10 Deployment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Device
      • 5.4.5.9 Material Type
      • 5.4.5.10 Deployment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Device
      • 5.4.6.9 Material Type
      • 5.4.6.10 Deployment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Device
      • 5.4.7.9 Material Type
      • 5.4.7.10 Deployment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Device
      • 5.5.1.9 Material Type
      • 5.5.1.10 Deployment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Device
      • 5.5.2.9 Material Type
      • 5.5.2.10 Deployment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Device
      • 5.5.3.9 Material Type
      • 5.5.3.10 Deployment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Device
      • 5.5.4.9 Material Type
      • 5.5.4.10 Deployment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Device
      • 5.5.5.9 Material Type
      • 5.5.5.10 Deployment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Device
      • 5.5.6.9 Material Type
      • 5.5.6.10 Deployment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Device
      • 5.6.1.9 Material Type
      • 5.6.1.10 Deployment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Device
      • 5.6.2.9 Material Type
      • 5.6.2.10 Deployment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Device
      • 5.6.3.9 Material Type
      • 5.6.3.10 Deployment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Device
      • 5.6.4.9 Material Type
      • 5.6.4.10 Deployment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Device
      • 5.6.5.9 Material Type
      • 5.6.5.10 Deployment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Sandoz
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Samsung Biologics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Biocon
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Catalent
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 WuXi Biologics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Lonza
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Sartorius
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Boehringer Ingelheim
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Fujifilm Diosynth Biotechnologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Abzena
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 AGC Biologics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Samsung Bioepis
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Cytiva
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Bavarian Nordic
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 MorphoSys
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us